Smith & Nephew
Logotype for Smith & Nephew plc

Smith & Nephew (SN) investor relations material

Smith & Nephew Q3 2026 TU earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Smith & Nephew plc
Q3 2026 TU earnings summary4 Nov, 2026

Executive summary

  • Q3 revenue grew 3.4% underlying and reported, accelerating from 1.6% in Q2; Sports Medicine & ENT led, Wound improved and Orthopaedics returned to growth.

  • More than 50% of Q3 growth came from products launched in the last five years.

  • Weaker US Hips and Knees trading prompted lower FY26 guidance.

Financial highlights

  • Q3 revenue was $1,551m versus $1,501m in Q3 2025; underlying and reported growth were both 3.4%, with no FX or trading-day impact.

  • Nine-month revenue was $4,648m versus $4,461m; underlying growth was 2.7% and reported growth was 4.2%.

  • Q3 business-unit revenue: Orthopaedics $590m, Sports Medicine & ENT $507m and Advanced Wound Management $454m.

  • Regional underlying growth was 3.0% in the US, 3.2% in Other Established Markets and 4.8% in Emerging Markets; excluding China, growth was 4.0%.

Outlook and guidance

  • FY26 underlying revenue growth is expected at ~3%, versus prior ~4%; reported growth is ~4.0% at 30 October exchange rates.

  • FY26 trading profit is expected at ~$1.25bn, with ~4% growth, versus prior ~$1.3bn and ~8% growth; profit growth is expected to remain ahead of revenue growth.

  • FY26 free cash flow is expected at ~$750m versus prior ~$800m; trading cash conversion is ~95% and ROIC is expected at ~9%.

  • China is expected to be broadly neutral to full-year growth; 2027 guidance and a medium-term outlook update are planned with Q4 results.

  • LANDMARK cemented launch is planned for Q2 2027, with meaningful traction expected in H2; CORI Hip and CORI Hip Impactor launches are planned for Q1 and Q3 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Smith & Nephew earnings date

Logotype for Smith & Nephew plc
Q4 20261 Mar, 2027
Smith & Nephew
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Smith & Nephew earnings date

Logotype for Smith & Nephew plc
Q4 20261 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Smith & Nephew plc manufactures and sells medical devices worldwide. It offers joint replacement products; sports medicine solutions, including arthroscopy, rehabilitation, and orthopedic reconstruction; and trauma and extremities solutions. The company sells its products through sales representatives, distributors, and direct sales force under the Advanced Wound Management, Sports Medicine, Arthroscopy and Biosurgery, Trauma and Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Bioactives and Advanced Wound Devices brands.